论文部分内容阅读
目的:研究结肠癌患者门静脉血细胞角蛋白20(CK20)mRNA对肝脏微转移的诊断价值。方法:采用RT-PCR技术对31例结肠癌患者的门静脉血进行检测。结果:结肠癌患者中CK20 mRNA阳性率为26%,本组随访时间6～32个月,平均(18.5±10.6)个月。术中1例患者出现肝转移并且门静脉血CK20为阳性,术时无肝脏转移而门静脉血CK20阳性的7例中3例出现肝转移,术时无肝转移和门静脉血CK20阴性的23例患者中2例(9%)出现肝转移。结论:结肠癌患者术中门静脉血CK20 mRNA的检测对于了解预后和指导治疗有着重要的参考价值。
OBJECTIVE: To investigate the diagnostic value of CK20 mRNA in portal vein of patients with colon cancer for hepatic micrometastasis. METHODS: RT-PCR was used to detect portal vein blood in 31 patients with colon cancer. Results: The positive rate of CK20 mRNA in patients with colon cancer was 26%. The follow-up time of this group was 6-32 months, with an average of (18.5±10.6) months. One patient had hepatic metastases and CK20 was positive in portal venous blood. Hepatic metastases occurred in 3 of 7 cases with no hepatic metastasis and CK20 in portal venous blood during operation. Among the 23 patients with hepatic metastasis and CK20-negative portal vein disease during surgery Liver metastases occurred in 2 patients (9%). Conclusion: Detection of CK20 mRNA in portal vein blood of patients with colon cancer has important reference value for understanding prognosis and guiding treatment.